Smart Patients Get Smart Care™
The World’s Leading Authority for Chronic Lymphocytic Leukemia Patients
Patients with acalabrutinib had lower discontinuation rates and a prolonged time to discontinuation compared to pts treated with ibrutinib.
We discuss enitociclib, an experimental CDK9 inhibitor in development for treating NHL and CLL.
A study that used real-world data to see what treatments are being given to patients with CLL / SLL who have received 2+ lines of therapy
May 2023 CLL Bloodline: The CLL Society Bloodline will teach the BASICS needed to understand CLL.
Starting treatment for CLL / SLL requires a complex decision-making process. There are several well-established choices
We discuss combination therapies for CLL and SLL, focusing on the combination of ibrutinib plus venetoclax.
Study shows that patients with relapsed/refractory CLL recovered immune function after fixed-duration treatment with venetoclax + rituximab.
Tremendous progress over the past decade has been made in managing chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL).
Innovation The Innovation pillar of CLL Society’s Policy Institute is critical, as it includes our efforts to address policies that could potentially inflate CLL / SLL drug prices and skew healthcare provider incentives.
One click to our most popular content.
